Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice.

[1]  T. Wade,et al.  Variable gene family usage of protective and non‐protective anti‐Vibrio cholerae O1 LPS antibody heavy chains , 2008, Microbiology and immunology.

[2]  Firdausi Qadri,et al.  Susceptibility to Vibrio cholerae Infection in a Cohort of Household Contacts of Patients with Cholera in Bangladesh , 2008, PLoS neglected tropical diseases.

[3]  Shu-jie Hou,et al.  Preparation of glycoconjugates by dialkyl squarate chemistry revisited. , 2008, Carbohydrate research.

[4]  S. Calderwood,et al.  Transcutaneous Immunization with Clostridium difficile Toxoid A Induces Systemic and Mucosal Immune Responses and Toxin A-Neutralizing Antibodies in Mice , 2007, Infection and Immunity.

[5]  Mercedes Pascual,et al.  Serotype cycles in cholera dynamics , 2006, Proceedings of the Royal Society B: Biological Sciences.

[6]  J. Shiloach,et al.  Immunogenicity of synthetic saccharide fragments of Vibrio cholerae O1 (Ogawa and Inaba) bound to Exotoxin A. , 2006, FEMS immunology and medical microbiology.

[7]  S. Calderwood,et al.  Transcutaneous Immunization with Toxin-Coregulated Pilin A Induces Protective Immunity against Vibrio cholerae O1 El Tor Challenge in Mice , 2006, Infection and Immunity.

[8]  P. Kováč,et al.  Length of the linker and the interval between immunizations influences the efficacy of Vibrio cholerae O1, Ogawa hexasaccharide neoglycoconjugates. , 2006, FEMS immunology and medical microbiology.

[9]  David A. Sack,et al.  Blood Group, Immunity, and Risk of Infection with Vibrio cholerae in an Area of Endemicity , 2005, Infection and Immunity.

[10]  P. Kováč,et al.  Effect of saccharide length on the immunogenicity of neoglycoconjugates from synthetic fragments of the O-SP of Vibrio cholerae O1, serotype Ogawa. , 2005, Carbohydrate research.

[11]  R. Rappuoli,et al.  Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate polyribosyl ribitol phosphate-cross-reacting material 197 vaccine. , 2004, The Journal of infectious diseases.

[12]  M. Meeks,et al.  Synthetic Fragments of Vibrio cholerae O1 Inaba O-Specific Polysaccharide Bound to a Protein Carrier Are Immunogenic in Mice but Do Not Induce Protective Antibodies , 2004, Infection and Immunity.

[13]  A. Faruque,et al.  Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. , 2004, The Journal of infectious diseases.

[14]  S. Calderwood,et al.  Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies. , 2002, Vaccine.

[15]  P. Alzari,et al.  Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier. , 2002, The Journal of infectious diseases.

[16]  F. Nato,et al.  Preparation, Immunogenicity, and Protective Efficacy, in a Murine Model, of a Conjugate Vaccine Composed of the Polysaccharide Moiety of the Lipopolysaccharide of Vibrio cholerae O139 Bound to Tetanus Toxoid , 2001, Infection and Immunity.

[17]  P. Kováč,et al.  Conjugating oligosaccharides to proteins by squaric acid diester chemistry: rapid monitoring of the progress of conjugation, and recovery of the unused ligand. , 2001, Carbohydrate research.

[18]  C. Alving,et al.  Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits, and Unrelated Adjuvants , 2000, Infection and Immunity.

[19]  S. Calderwood,et al.  In Vitro and In Vivo Analyses of Constitutive and In Vivo-Induced Promoters in Attenuated Vaccine and Vector Strains ofVibrio cholerae , 2000, Infection and Immunity.

[20]  S. Calderwood,et al.  Optimizing the Germfree Mouse Model for In Vivo Evaluation of Oral Vibrio cholerae Vaccine and Vector Strains , 2000, Infection and Immunity.

[21]  G. Matyas,et al.  Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins as Antigens and Adjuvants , 1999, Infection and Immunity.

[22]  C. Alving,et al.  Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. , 1998, Journal of immunology.

[23]  David N. Taylor,et al.  Phase 1 Evaluation of Vibrio choleraeO1, Serotype Inaba, Polysaccharide-Cholera Toxin Conjugates in Adult Volunteers , 1998, Infection and Immunity.

[24]  G. Matyas,et al.  Skin immunization made possible by cholera toxin , 1998, Nature.

[25]  C. Wennerås,et al.  Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1 , 1997, Infection and immunity.

[26]  E. Ryan,et al.  Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice , 1997, Infection and immunity.

[27]  S. Calderwood,et al.  Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain , 1997, Infection and immunity.

[28]  M. Levine,et al.  Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity , 1997, Clinical and diagnostic laboratory immunology.

[29]  E. Ryan,et al.  Development of a germfree mouse model of Vibrio cholerae infection , 1996, Infection and immunity.

[30]  J. Holmgren,et al.  Immune mechanisms and protective antigens of Vibrio cholerae serogroup O139 as a basis for vaccine development , 1996, Infection and immunity.

[31]  J. Mekalanos,et al.  Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo , 1993, Infection and immunity.

[32]  Y. Haishima,et al.  Occurrence of 2-O-methyl-N-(3-deoxy-L-glycero-tetronyl)-D-perosamine (4-amino-4,6-dideoxy-D-manno-pyranose) in lipopolysaccharide from Ogawa but not from Inaba O forms of O1 Vibrio cholerae. , 1993, Biochemical and biophysical research communications.

[33]  R. Gupta,et al.  Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin , 1992, Infection and immunity.

[34]  R. Schneerson,et al.  Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age. , 1991, The Pediatric infectious disease journal.

[35]  R Weltzin,et al.  New model for analysis of mucosal immunity: intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumors protects against Vibrio cholerae infection , 1991, Infection and immunity.

[36]  J. Holmgren,et al.  Vibrio cholerae expresses cell surface antigens during intestinal infection which are not expressed during in vitro culture , 1989, Infection and immunity.

[37]  R. Glass,et al.  Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. , 1985, The Journal of infectious diseases.

[38]  D. Sack,et al.  Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. , 1984, The Journal of infectious diseases.

[39]  J. Holmgren,et al.  Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid , 1976, Infection and immunity.

[40]  W. Mosley,et al.  Characteristics of the serum vibriocidal and agglutinating antibodies in cholera cases and in normal residents of the endemic and non-endemic cholera areas. , 1970, Journal of immunology.

[41]  W. Mosley,et al.  A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. , 1968, Bulletin of the World Health Organization.

[42]  W H Mosley,et al.  A serological survey for cholera antibodies in rural east Pakistan. 2. A comparison of antibody titres in the innunized and control populationd of a cholera-vaccine field-trial area and the relation of antibody titre to cholera case rate. , 1968, Bulletin of the World Health Organization.

[43]  R. F. Chen,et al.  Removal of fatty acids from serum albumin by charcoal treatment. , 1967, The Journal of biological chemistry.